Ye Yang1, Yujun Long1, Dongyu Kang1, Chenchen Liu1, Jingmei Xiao1, Renrong Wu2, Jingping Zhao1. 1. National Clinical Research Center for Mental Disorders, and Department of Psychiatry, The Second Xiangya Hospital of Central South University, 410011, Hunan, China. 2. National Clinical Research Center for Mental Disorders, and Department of Psychiatry, The Second Xiangya Hospital of Central South University, 410011, Hunan, China. wurenrong@csu.edu.cn.
Abstract
RATIONALE: Gut microbiota plays an important role in host metabolism. Antipsychotic drugs can result in metabolic abnormalities. Probiotics may ameliorate the antipsychotic drug-induced metabolic abnormalities by regulating gut microbiota. OBJECTIVE: To determine whether Bifidobacterium intervention can ameliorate olanzapine-induced weight increase. METHODS: Enrolled patients were assigned to either the olanzapine or olanzapine plus Bifidobacterium group. The following were assessed: body weight, body mass index (BMI), appetite, latency to increased appetite, and baseline weight increase of more than 7%. All assessments were conducted at baseline and at 4, 8, and 12 weeks of treatment. RESULTS: We enrolled 70 patients with schizophrenia or schizophrenic affective disorder, and 67 completed the study. Treatment for 4 weeks led to between-group differences in weight change (2.4 vs. 1.1 kg, p < 0.05) and BMI (0.9 vs. 0.4, p < 0.05). However, this difference disappeared at 8 and 12 weeks of treatment (both p > 0.05). The two groups did not differ in appetite increase at any time point (p > 0.05). The mean time from olanzapine initiation to appetite increase was also not significantly different between the two groups (t = 1.243, p = 0.220). CONCLUSIONS: Probiotics may mitigate olanzapine-induced weight gain in the early stage of treatment and delay olanzapine-induced appetite increase.
RCT Entities:
RATIONALE: Gut microbiota plays an important role in host metabolism. Antipsychotic drugs can result in metabolic abnormalities. Probiotics may ameliorate the antipsychotic drug-induced metabolic abnormalities by regulating gut microbiota. OBJECTIVE: To determine whether Bifidobacterium intervention can ameliorate olanzapine-induced weight increase. METHODS: Enrolled patients were assigned to either the olanzapine or olanzapine plus Bifidobacterium group. The following were assessed: body weight, body mass index (BMI), appetite, latency to increased appetite, and baseline weight increase of more than 7%. All assessments were conducted at baseline and at 4, 8, and 12 weeks of treatment. RESULTS: We enrolled 70 patients with schizophrenia or schizophrenic affective disorder, and 67 completed the study. Treatment for 4 weeks led to between-group differences in weight change (2.4 vs. 1.1 kg, p < 0.05) and BMI (0.9 vs. 0.4, p < 0.05). However, this difference disappeared at 8 and 12 weeks of treatment (both p > 0.05). The two groups did not differ in appetite increase at any time point (p > 0.05). The mean time from olanzapine initiation to appetite increase was also not significantly different between the two groups (t = 1.243, p = 0.220). CONCLUSIONS: Probiotics may mitigate olanzapine-induced weight gain in the early stage of treatment and delay olanzapine-induced appetite increase.
Entities:
Keywords:
Appetite; Bifidobacterium; Olanzapine; Schizophrenia; Weight gain
Authors: Jonathan Breton; Naouel Tennoune; Nicolas Lucas; Marie Francois; Romain Legrand; Justine Jacquemot; Alexis Goichon; Charlène Guérin; Johann Peltier; Martine Pestel-Caron; Philippe Chan; David Vaudry; Jean-Claude do Rego; Fabienne Liénard; Luc Pénicaud; Xavier Fioramonti; Ivor S Ebenezer; Tomas Hökfelt; Pierre Déchelotte; Sergueï O Fetissov Journal: Cell Metab Date: 2015-11-24 Impact factor: 27.287
Authors: N B Dass; A K John; A K Bassil; C W Crumbley; W R Shehee; F P Maurio; G B T Moore; C M Taylor; G J Sanger Journal: Neurogastroenterol Motil Date: 2007-01 Impact factor: 3.598
Authors: Kieran J Davey; Siobhain M O'Mahony; Harriet Schellekens; Orla O'Sullivan; John Bienenstock; Paul D Cotter; Timothy G Dinan; John F Cryan Journal: Psychopharmacology (Berl) Date: 2012-01-11 Impact factor: 4.530
Authors: K J Davey; P D Cotter; O O'Sullivan; F Crispie; T G Dinan; J F Cryan; S M O'Mahony Journal: Transl Psychiatry Date: 2013-10-01 Impact factor: 6.222
Authors: Raghunath Singh; Nicolette Stogios; Emily Smith; Jiwon Lee; Kateryna Maksyutynsk; Emily Au; David C Wright; Giada De Palma; Ariel Graff-Guerrero; Philip Gerretsen; Daniel J Müller; Gary Remington; Margaret Hahn; Sri Mahavir Agarwal Journal: Ther Adv Psychopharmacol Date: 2022-05-15